Drug intelligence / Profile preview

XR-B

Development stage: Preclinical
Modality: Small Molecules, Device-based Delivery → Drug Delivery Systems
Administration: Subcutaneous

Overview

XR-B, an abbreviation for extended-release buprenorphine, is a pharmaceutical drug class primarily used for the treatment of opioid use disorder (OUD). It functions as a partial opioid agonist, providing a sustained release of buprenorphine to help manage opioid dependence and withdrawal symptoms. This formulation is typically administered via monthly subcutaneous injections, offering a convenient and effective treatment option. Notable examples of extended-release buprenorphine formulations include Sublocade and Brixadi.

Other names: extended-release buprenorphine

Targets

MOR (Mu opioid receptor)

Beyond the preview

Go deeper on XR-B.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XR-B.

Explore the full profile